United States - English - NLM (National Library of Medicine)

bryant ranch prepack - aripiprazole (unii: 82vfr53i78) (aripiprazole - unii:82vfr53i78) - aripiprazole 5 mg - aripiprazole oral tablets are indicated for the treatment of: - schizophrenia [see clinical studies ( 14.1) ] - acute treatment of manic and mixed episodes associated with bipolar i disorder [see clinical studies ( 14.2) ] - adjunctive treatment of major depressive disorder [see clinical studies ( 14.3) ] - irritability associated with autistic disorder [see clinical studies (

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; hyprolose; colloidal anhydrous silica; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; magnesium stearate; colloidal anhydrous silica; hyprolose; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 10 mg - tablet, uncoated - excipient ingredients: magnesium stearate; microcrystalline cellulose; maize starch; lactose monohydrate; hyprolose; colloidal anhydrous silica - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 20 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; hyprolose; maize starch; microcrystalline cellulose; colloidal anhydrous silica - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 2 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; lactose monohydrate; iron oxide yellow; colloidal anhydrous silica; hyprolose; indigo carmine aluminium lake; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; colloidal anhydrous silica; hyprolose; lactose monohydrate; magnesium stearate; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 15 mg - tablet, uncoated - excipient ingredients: colloidal anhydrous silica; hyprolose; lactose monohydrate; magnesium stearate; maize starch; microcrystalline cellulose - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; indigo carmine aluminium lake; microcrystalline cellulose; lactose monohydrate; hyprolose; colloidal anhydrous silica; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - aripiprazole, quantity: 5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; indigo carmine aluminium lake; hyprolose; magnesium stearate; microcrystalline cellulose; maize starch - aripiprazole is indicated for the treatment of schizophrenia including maintenance of clinical improvement during continuation therapy.